129 results about "Metformin hcl" patented technology

The invention discloses a preparation method of metformin hydrochloride. The preparation method is characterized by using dicyandiamide and dimethylamine hydrochloride as raw materials, feeding the materials in a mole ratio of (1:1)-(1:1.2), using N,N-dimethylacetamide or dimethyl sulfoxide 2-4 times dicyandiamide by weight as a solvent, and reacting for 4-8 hours at 140+/-5 DEG C to prepare a crude metformin hydrochloride product; recrystallizing the crude product with ethanol, regulating the pH value to be 5-6, decoloring the crystal, cooling the crystal to minus 10-0 DEG C while stirring, precipitating the crystal, obtaining a refined metformin hydrochloride product through filtering and drying, and recovering the solvent from filtrate. The qualified product has yield of 80-85% and high purity. The preparation method has the advantages that as the selected reaction solvent has a relatively high boiling point, the recovery rate of the solvent is high; the phenomenon of material surging can be effectively avoided, so that the preparation method has the advantages of mild reaction conditions, simplicity in operation and high safety.

The invention relates to a composition containing repaglinide and metformin hydrochloride and a preparation method thereof, belonging to the technical field of medicines. The composition containing repaglinide and metformin hydrochloride consists of repaglinide, metformin hydrochloride, a filling agent, a disintegrating agent, a bonding agent, a latent solvent and a lubricant, wherein the repaglinide is added into the metformin hydrochloride and auxiliary materials in the form of aqueous solution for wet granulation. The preparation method has the advantages of simple and efficient process, small using quantity of auxiliary materials, capability of solving the problem of poor content uniformity caused by small using amount of the repaglinide and increase in the dissolution rate; and moreover, a preparation has a smaller unit quantity and can be applied to industrial mass production.

The present invention is based on the unexpected discovery that a combination of certain known drugs exhibits synergistic effects in treating metabolic syndrome and various other diseases. In particular, the invention comprises a pharmaceutical composition comprising: (1) a therapeutically effective quantity of a first agent that is an AMPK activator; and (2) a therapeutically effective quantity of a second agent that possesses or maintains serotonin activity. A preferred composition comprises metformin hydrochloride and melatonin. The invention further comprises methods for the use of these compositions for the treatment of metabolic syndrome, hyperproliferative diseases including cancer, and other diseases and conditions.

The invention relates to an antidiabetic pharmaceutical composition, more specifically to a pharmaceutical composition containing a DPP-4 inhibitor and metformin hydrochloride and a preparation method thereof. The composition contains DPP-4 inhibitor and metformin hydrochloride two active components, and meglumine as the stabilizer. The pharmaceutical composition has excellent storage stability and excellent dissolution characteristics. The invention also provides a preparation method of the composition, the auxiliary materials of the preparation technology are easily available and low in price, thus being suitable for industrial production.

The invention relates to a method for preparing fluorescent carbon quantum dots by taking metformin as a precursor. The method comprises the following steps: step 1, carrying out hydrothermal reactionon metformin hydrochloride and dithiodibenzoic acid to generate a carbon quantum dot stock solution; step 2, filtering out impurities from the carbon quantum dot stock solution to form filtrate; step3, after the filtrate is subjected to heating and magnetic stirring treatment, attaching carbon quantum dots in the filtrate to a first filter membrane through the first filter membrane; and step 4,drying the first filter membrane to obtain carbon quantum dot powder. The purity of the final product is higher than that of fluorescent carbon dots with natural organic matter as a carbon source, thereaction process and structure can be analyzed, no toxic reagent is added, the operation method is simple and convenient, and finally the fluorescent carbon quantum dots with high fluorescence emission intensity can be prepared on a large scale.

The present invention provides a new method for determining metformin hydrochloride content by using an ion selective electrode method. According to the present invention, a pCL-1Q9 type chloride ion selective electrode is adopted as a work electrode, a 217 type saturated calomel electrode is adopted as a reference electrode, a stirring rate is 120 rpm/min, a stirring time is 3 min, the pH value is 4-6, a temperature is 18 DEG C, a buffer solvent is a total ionic strength adjustment buffer solution comprising potassium nitrate and sodium citrate, and a standard curve method is adopted as the method for quantitative analysis of the drug metformin hydrochloride effective component content; and compared with the traditional method, the method of the present invention has characteristics of simple experiment equipment, low test cost, simpleness, rapidness, accurate determination result, wide linear range and high sensitivity, and is the easiest and feasible analysis method for determining the metformin hydrochloride content.

The invention discloses anti-breast cancer powder containing metformin hydrochloride and gdc0941. Active components of the anti-breast cancer powder are the metformin hydrochloride and gdc 0941. The anti-breast cancer powder further comprises pharmaceutically acceptable auxiliary materials. The anti-breast cancer powder is simple to prepare, easy to operate, lower in cost and economical and practical; the anti-breast cancer powder disperses easily and takes effect fast, and dosage of the powder is easily controllable; in-vitro antitumor tests show that the combination of the metformin hydrochloride and gdc 0941 provides higher anti-cancer activity and the powder is worthy of clinical popularization.

The invention relates to the technical field of pharmaceutical preparations, and discloses a sitagliptin metformin tablet preparation and a preparation method thereof. The preparation is prepared from metformin hydrochloride, sitagliptin phosphate monohydrate, an adhesive and a lubricant through a hot melt extrusion method. According to the invention, a hot melt extrusion technology is adopted, metformin hydrochloride and an adhesive are mixed, the mixture is melted, extruded and conveyed in a hot melt extruder to obtain solid dispersion strips, the solid dispersion strips are cut off, crushed and sieved, the sieved solid dispersion strips are mixed with sitagliptin phosphate monohydrate, and then a lubricant is added for mixing, so that prepared particles are uniform and have better fluidity and good compressibility; in the production process, few auxiliary materials are needed, the production cost is reduced, the production procedures are reduced, the content and content uniformity of the obtained product far exceed the product quality requirements, the reproducibility is good, continuous operation can be achieved, continuous production is achieved, and the difference between batches is reduced.

An orally taken solid medicine for treating the insulin independent diabetics is prepared from meguan, disintegrant, filler, swelling additive, flowing aid, and other medicinal auxiliary or carrier.

The invention discloses anti-breast cancer granules combining metformin hydrochloride and gdc 0941. Active components of the anti-breast cancer granules are metformin hydrochloride and gdc 0941. The anti-breast cancer granules further comprise pharmaceutically acceptable auxiliary materials. The anti-breast cancer granules are simple to prepare, easy to operate, lower in cost and economical and practical; the anti-breast cancer granules are portable, dissolve fast, are well absorbable and take effect fast. In-vitro antitumor tests show that anti-cancer activities of the metformin hydrochloride and gdc 0941 are synergistic, the combination of the metformin hydrochloride and gdc 0941 provides high anti-cancer activity, high cost of a single dose can be decreased, and the anti-breast cancer granules are worthy of clinical popularization.